You have probably taken a round of antibiotics at some point. Most people never think about what happens to the rest of their gut while the drug is doing its job.
For a small number, that collateral damage opens the door to something far worse.
Researchers in Germany have identified a natural compound called argyrin B that killed Clostridioides difficile, a dangerous gut bacterium, in mice.
The compound left the beneficial bacteria in the gut largely alone.
Also read: Can sauna sessions help reduce depression? Here's what researchers found
The findings were published in npj Antimicrobials and Resistance.
The work came from the Helmholtz Institute for Pharmaceutical Research Saarland, with partners at Hannover Medical School and Saarland University.
The problem with current treatment is simple. The drugs that clear a C. difficile infection also wipe out the healthy microbes that normally keep C. difficile in check. The infection often comes roaring back weeks later.
The CDC estimates nearly half a million C. difficile infections in the United States every year. Tens of thousands of patients die, most of them adults over 65.
Also read: New COVID-19 variant spreads: Here are 14 symptoms you should know
The mouse study
Argyrin B comes from soil-dwelling myxobacteria.
These are microbes long known for making compounds that attack other bacteria.
In the mouse study, oral argyrin B sharply dropped the C. difficile load. The effect matched vancomycin, the standard antibiotic, and worked at much lower doses.
Crucially, mice given argyrin B kept most of their healthy gut bacteria. Vancomycin, by contrast, flattened many of the same beneficial bugs it was supposed to leave alone.
Also read: A new herpes drug just got FDA approval for cases where nothing else works
The compound also stayed where it was needed. Taken by mouth, argyrin B remained in the large intestine, with little of it entering the bloodstream. That is exactly where C. difficile lives.
The team also pinned down how it works. Argyrin B blocks a bacterial protein called elongation factor G, which bacteria need to build other proteins. The target is different from the one existing C. difficile drugs attack.
Why protecting gut bacteria matters so much
After a first bout of C. difficile, between 15 and 25 percent of patients get the infection again.
The reason is the same antibiotic that clears the first bout also kills the microbial community that would otherwise crowd C. difficile out.
Also read: Needles hurt less when you listen to this kind of music, study finds
The team sees argyrin B's narrow spectrum as the key feature.
In the Helmholtz Institute news release in EurekAlert, senior scientist Jennifer Herrmann said "the gut microbiome could therefore be spared during treatment with argyrin."
The results come from laboratory tests and a mouse infection model, not from people. The next step for the team is to work out dosing and test whether argyrin B can prevent the repeat bouts that make C. difficile so punishing in human patients.
Anyone with ongoing diarrhea in the days or weeks after a hospital stay or a course of antibiotics should talk to a doctor rather than wait it out.
Also read: Huge salmonella outbreak: River closed in Virginia
This article is made and published by Ida-Marie Palm Varbæk, who may have used AI in the preparation.